PARKINSON’S DISEASE AND MENTAL HEALTH

MARK W NEWMAN MD
DEPARTMENT OF PSYCHIATRY
UW SCHOOL OF MEDICINE
GENERAL DISCLOSURES

The University of Washington School of Medicine also gratefully acknowledges receipt of educational grant support for this activity from the Washington State Legislature through the Safety-Net Hospital Assessment, working to expand access to psychiatric services throughout Washington State.
GENERAL DISCLOSURES

UW PACC is also supported by Coordinated Care of Washington
SPEAKER DISCLOSURES

✓ No conflicts of interest

PLANNER DISCLOSURES

The following series planners have no relevant conflicts of interest to disclose:

Mark Duncan MD          Cameron Casey
Barb McCann PhD          Betsy Payn
Anna Ratzliff MD PhD    Diana Roll
Rick Ries MD             Cara Towle MSN RN
Kari Stephens PhD        Niambi Kanye
"A more melancholy object I never beheld. The patient, naturally a handsome, middle-sized, sanguine man, of a cheerful disposition, and an active mind, appeared much emaciated, stooping, and dejected."

James Parkinson, Royal College of Surgeons
“An Essay on the Shaking Palsy”
London, 1817
OBJECTIVES

1. Understand relative frequency of psychiatric syndromes in Parkinson’s Disease
2. Understand options for treatment of PD related psychosis
ROAD MAP

1. Case Vignette
2. Overview and Epidemiology
3. Psychiatric Disorders
4. Treatment
A 64 YO WOMAN PRESENTS...

- Lives alone, executive assistant for university
- Dx with Parkinson’s Disease 5 years ago
- Meds include:
  - Sinemet 50-200 tid
  - ropinirole 6mg tid
  - amantadine 137mg qhs
A 64 YO WOMAN PRESENTS...

- anxiety and stress in her workplace
- coworkers working together to “push me out”
- upstairs neighbors are drug dealers
- surveilling her through cameras
- “chemical smells” from condo
“QUINTESSENTIAL”
NEUROPSYCHIATRIC DISORDER

Second most common neurodegenerative d/o
QUESTION

Which category of psychiatric disorders is most common in PD?

a. Mood Disorders
b. Psychosis
c. Anxiety Disorders
d. Sleep Disorders
PSYCHIATRIC DISORDERS IN PD

- Sleep Disorders
- All Psychosis
- All Anxiety
- Apathy
- All Depression
- Impulse Control Disorders

Percentage of occurrence: 0% to 100%
ROAD MAP

1. Case Vignette
2. Overview and Epidemiology
3. Psychiatric Disorders
4. Treatment
SLEEP DISORDERS ARE UBIQUITOUS

- 75-90% patients report sleep disruptions
  - Insomnia
  - Hypersomnia/excessive daytime sleepiness

- REM Sleep Behavior Disorder
  - Typically precedes diagnosis of PD
  - Failure of REM paralysis → act out vivid dreams
  - Distressing, possibly dangerous to bed partners
BROAD RANGE OF PSYCHOTIC SX

Severity/Distress

- "Minor Hallucinations"
- Visual Hallucinations
- Auditory/Olfactory Hallucinations
- Delusions
RISK FACTORS FOR PSYCHOSIS

1. Use of dopaminergic agents (dosage not clear assoc)
2. Presence of Dementia
3. Presence of sleep disorders (REM Behavior Disorder)
4. Age
5. Disease Progression
ANXIETY IS COMMON BUT UNDER-STUDIED

- Often discrete anxiety/panic attacks
- Also presents as social phobia and GAD
APATHY ≠ DEPRESSION

- Marked loss of motivation
- not attributable to emotional distress, intellectual impairment, or altered consciousness
QUESTION

What particular challenges might there be in detecting depression in a patient with Parkinson’s Disease?
DETECTING DEPRESSION IS COMPLEX

~25% PD patients on antidepressant at any given time

Instead of PHQ-9, consider
- Geriatric Depression Scale
- Beck Depression Inventory

MDD
- sadness
- guilt
- self-criticism

PD
- fatigue
- motor slowing
- cog slowing
- sleep disturbance
- restricted affect

$\sim$25\%$~25\%$ PD patients on antidepressant at any given time
IMPULSE CONTROL DISORDERS ARE UNDER-DIAGNOSED

- E.g. compulsive gambling, sexual behavior, trichotillomania, eating, etc
- ~14% annual, cumulative 5 year incidence 46% in one study.
- *Unlikely to self-report.*

Risk Factors
- dopamine agonists
- hx of SUD/gambling, male, early PD onset
PATTERN TO PSYCHIATRIC SYMPTOMS

One study in Norway performed hierarchical cluster analysis on 139 PD patients, finding 5 “clusters”

<table>
<thead>
<tr>
<th>Percentage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>42%</td>
<td>Mild depression, few other sx</td>
</tr>
<tr>
<td>29%</td>
<td>Mostly Psychotic sx</td>
</tr>
<tr>
<td>14%</td>
<td>Sleep disturbance, few other sx</td>
</tr>
<tr>
<td>8%</td>
<td>Severe depression &amp; anxiety</td>
</tr>
<tr>
<td>7%</td>
<td>Multiple severe sx across categories</td>
</tr>
</tbody>
</table>
ROAD MAP

1. Case Vignette
2. Overview and Epidemiology
3. Psychiatric Disorders
4. Treatment
BACK TO CLINICAL VIGNETTE...

- 64 yo woman with PD, psychotic symptoms that are impairing/distressing
- On 3 PD meds (managed by Neurology)
  - Sinemet 50-200 tid
  - ropinirole 6mg tid
  - amantadine 137mg qhs

Ideas for management?
MANAGEMENT OF PD PSYCHOSIS

One Approach

1. R/o delirium
2. Reduce or d/c other meds (antichol, BZDs, opiates, etc)
3. Reduce or d/c PD meds (amantadine, dopamine agonists, MAOB inhibitors, L-dopa)
4. Consider anti-psychotic

Is treatment necessary?
ANTI-PSYCHOTICS FOR PD PSYCHOSIS

- Quetiapine
  - Frequently used though insufficient evidence
  - 3 DBPCT found no benefit for psychosis, no worsening of motor sx

- Olanzapine
  - several studies show no benefit + worse motor sx

- Clozapine
  - multiple studies show improvement in psychosis, no effect on motor sx
  - sedation and orthostatic hypotension are major s/e
  - low doses (eg 6.25-50mg daily)
PIMAVANSERIN IS FDA APPROVED

- 5HT2A inverse agonist
- No activity at dopaminergic, muscarinic, adrenergic, histaminergic receptors
- Mean increase 7.3ms in QTc
- Few adverse effects, + FDA warning for increased mortality
- 34mg daily, no titration needed
Bupropion has the best evidence for treatment of MDD in Parkinson’s Disease.

a. True
b. False
MANAGEMENT OF DEPRESSION IN PD

SSRIs
- Citalopram & sertraline best evidence (also + studies for paroxetine, fluoxetine)
- Overall improvement but few remissions

Other ADs
- positive studies for venlafaxine
- Bupropion: few positive case reports but no controlled studies
- Positive meta-analysis for desipramine and nortriptyline

MAO-I:
- rasagiline and selegiline (irreversible selective MAO-B inhibitors) used for motor sx
- Selegiline esp may improve both depression and motor function.
- Review of 4500 patients on selegiline (≤10mg) and other AD found 0.24% reported sx of SS
MANAGEMENT OF DEPRESSION IN PD

CBT
- Only 2 small RCTs, both positive

ECT
- Review of case reports, chart reviews, and case-control studies
  - 93% some improvement in depressive symptoms
  - 83% some improvement in motor symptoms

rTMS
- Placebo-controlled studies did not find significant effect
MANAGEMENT OF OTHER DISORDERS

Anxiety
- No high quality RCTs
- Rec SSRI or buspirone

Apathy
- Some evidence for:
  - Piribedil (dopamine agonist)
  - Rivastigmine (cholinesterase inhibitor)
- Negative study for bupropion
- Behavioral Activation
  - regular routines
  - socialization
MANAGEMENT OF OTHER DISORDERS

Impulse Control Disorders

- High quality negative study for naltrexone
- Low quality positive study for CBT
- Behaviors often resolve with d/c of dopamine agonist
CLINICAL VIGNETTE CONCLUSION

- Coordinated with Neurology to:
  - Stop amantadine
  - Reduce dose of ropinirole
- Started quetiapine, titrate to 25mg qam + 75mg qhs
- Paranoia and olfactory hallucinations resolved over ~4 months
REFERENCES